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Randomization Analyses
in Selection of Secretory
Phospholipase A2-IIA as a
Valid Therapeutic Target for
Prevention of Cardiovascular
Disease
Holmes et al. (1) investigated the association between secretory
phospholipase A2-IIA (sPLA2-IIA) as a potential therapeutic
target for prevention of cardiovascular disease, using observational
studies between the PLA2G2A rs11573156 variant and cardiovas-
cular events, and deductions from published data with the pan-
sPLA2 inhibitor varespladib methyl. The validity of the analysis by
Holmes et al. remains unclear due to inaccurate summary of data,
incorrect assumptions related to the biology of sPLA2-IIA, and the
pharmacological effects of varespladib (2). For brevity, the major
issues include the following:
1. No reporting of the absolute values for sPLA2-IIA levels and
activity, which is important because of variable results with
different analytical methods and marked differences in
sPLA2 levels that result from the acute phase reaction in
patients with acute coronary syndrome versus patients with
stable coronary heart disease;
2. Use of total sPLA2 activity as a surrogate for sPLA2-IIA
activity;
3. Investigation of the PLA2G2A rs11573156 variant with
messenger RNA expression even though none of the variants
illustrated in Figure 2 included the variant as a genetic tool
in the current analysis;
4. A marginally signiﬁcant correlation between PLA2G2A
rs11573156 variant and sPLA2 activity despite highercorrelations between sPLA2-IIA mass and sPLA2 activity
reported in Online Figure 2;
5. Reporting of percentage changes in sPLA2 levels and sPLA2
activity when absolute changes may be more important,
particularly because of wide differences in baseline sPLA2-
IIA levels in different cohorts;
6. A lack of clear presentation from the original studies of the
reported effects of varespladib on sPLA2-IIA mass, and in
fact, the table understates the effect of varespladib 500 mg/
day on sPLA2-IIA mass by more than 50%, whereas the
reduction is 80%; the authors concluded incorrectly that the
homozygous rs11573156C allele resulted in a reduction in
sPLA2-IIA mass “similar” to the effect of varespladib;
7. Biomarker effects of sPLA2 in randomized clinical trials
with >500 subjects should have included only the FRANCIS
(Fewer Recurrent Acute Coronary Events With Near-Term
Cardiovascular Inﬂammation Suppression)-ACS trial on the
basis of the sample size requirement, but 3 trials are reported;
8. Biomarker effects should have been reported from the
PLASMA I (Phospholipase Levels And Serological
Markers of Atherosclerosis) and PLASMA II (Phospholi-
pase Levels And Serological Markers of Atherosclerosis II)
trials because these trials reported results from clinically
stable patients, whereas the FRANCIS-ACS trial mandated
a change in statin therapy for all patients to atorvastatin 80
mg daily regardless of their prior statin regimen;
9. Varespladib is a pan-sPLA2 inhibitor with similar efﬁcacy in
lowering groups IIA and X sPLA2 with somehow lower
potency against group V, despite the incorrect data cited in
this report (3).
Moreover, the use of Mendelian randomization studies to deduce
pharmacological effects does not account for the properties of the
speciﬁc inhibitor. Speciﬁcally, varespladib is hydrophilic and may
not penetrate into vascular tissues with sufﬁcient potency to reduce
intracellular effects versus the consistent effects on plasma bio-
markers. Also, because varespladib methyl inhibits sPLA2-X and a
recent report by Ait-Oufella et al. (4) demonstrated that over-
expression of sPLA2-X is atheroprotective, nonspeciﬁc effects of
varespladib as a pan inhibitor may have positive and negative effects.
In addition, preliminary results from theVISTA-16 trial (Evaluation
of Safety and Efﬁcacy of Short-term A-002 Treatment in Subjects
With Acute Coronary Syndrome) indicate an increase in myocardial
infarctions, so the effect of varespladib was harmful (5). As discussed
previously, proinﬂammatory pathways are redundant, and multiple
anti-inﬂammatory pathways modulate inﬂammatory responses.
In conclusion, careful review of primary data and cautious con-
clusions must be considered in these pharmacogenetic analyses (6).*Robert S. Rosenson, MD
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Randomization Analyses in
Selection of Secretory
Phospholipase A2-IIA as a
Valid Therapeutic Target for
Prevention of Cardiovascular DiseaseWe appreciate the remarks of Drs. Rosenson and Hurt-Camejo
regarding our work (1). We agree that the association of levels of
secretory phospholipase A2-IIA (sPLA2-IIA) mass and sPLA2
enzyme activity may differ in subjects with and without coronary
heart disease (CHD). For this reason, all analyses were conducted
separately for the general population and for those with acute
coronary syndrome.
As expressed in multiple places throughout the report, sPLA2
activity was not used as a proxy of sPLA2-IIA activity but as a
composite of several sPLA2 isoenzymes.
The single nucleotide polymorphism showing the strongest as-
sociation with PLA2G2A messenger RNA expression (rs10732279)
was in very strong linkage disequilibrium (R2 ¼ 0.91) with the
PLA2G2A rs11573156 variant used for our Mendelian randomi-
zation analysis.
The correlation between sPLA2-IIA mass and sPLA2 enzyme
activity was moderate at best and does not imply a similar
magnitude of association of the PLA2G2A rs11573156 variant
with both of these measures. Because the mass assay is speciﬁc for
sPLA2-IIA, but the activity assay is not, it is not surprising that
rs11573156 showed a stronger association with mass than with
activity.
sPLA2-IIA mass and sPLA2 enzyme activity were non-
normally distributed, and therefore, these variables were log
transformed for analysis. The difference in log values equates to theproportional difference in sPLA2-IIA mass and activity between
the 2 groups.
The correspondents failed to read Online Table 11 carefully, in
which values are differences in sPLA2-IIA mass on the absolute
scale from treatment with 500 mg/day varespladib versus placebo
pooled across the randomized controlled trials. The value (13.13
pmol/l) for sPLA2-IIA mass corresponds to a 78% reduction in
sPLA2-IIA mass (reported in the Results section), which is com-
parable to the 80% value to which the correspondents refer.
We did not specify a cut point of 500 participants for the
inclusion of trial data; however, we reported information on the
pooled effects of varespladib on biomarkers available in more
than 500 subjects in total across all trials of varespladib.
We did not ﬁnd evidence of a differential effect of varespladib
on sPLA2-IIA mass or low-density lipoprotein cholesterol level
when stratiﬁed by trials of patients with acute coronary syndrome
or stable CHD (p ¼ 0.48 and p ¼ 0.42 for heterogeneity,
respectively).
The review cited by the correspondents refers to 2 identical
studies that we discussed (Online Fig. 1) and cited, providing ev-
idence that the median inhibitory concentration values for vares-
pladib are lower for IIA (9 to 14 nmol/l) than for V or X (77 and 15
nmol/l, respectively).
We agree that varespladib is a nonspeciﬁc sPLA2 inhibitor,
and the genetic variant we studied was speciﬁc for sPLA2-IIA
mass. This is why we stated repeatedly that our analysis informs
on sPLA2-IIA as a therapeutic target, but not other sPLA2
isoforms.
We stand by the validity of our study and maintain our
conclusion that sPLA2-IIA is unlikely to play a causal role in
CHD.*Michael V. Holmes, MBBS, MSc
Tabassome Simon, MD, PhD
Holly J. Exeter, PhD
Aroon D. Hingorani, MBBS, PhD
Marc S. Sabatine, MD, PhD
Ziad Mallat, MD, PhD
Juan P. Casas, MD, PhD
Philippa J. Talmud, DSc
on behalf of all coauthors
*Faculty of Population Health Sciences
Department of Epidemiology and Public Health
University College London
Torington Place
London WC1E 6BT
England
E-mail: mvholmes@gmail.com
http://dx.doi.org/10.1016/j.jacc.2013.10.070
Please note: Drs. Mallat and Simon are listed as coinventors on patents related to the
use of sPLA2 activity and/or PLA2G2A rs11573156 single nucleotide polymorphism as
a cardiovascular biomarker. All other authors have reported that they have no
relationships relevant to the content of this paper to disclose.REFERENCE
1. Holmes MV, Simon T, Exeter HJ, et al. Secretory phospholipase
A2-IIA and cardiovascular disease: a Mendelian randomization study.
J Am Coll Cardiol 2013;62:1966–76.
